Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127477401 | 12747740 | 1 | I | 20160831 | 20160915 | 20160915 | EXP | PK-IPCA LABORATORIES LIMITED-E2B_00000031 | IPCA | RASHID O,FAROOQ S,KIRAN Z,ISLAM N. EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES STARTED ON EMPAGLI?OZIN. BMJ CASE REP 2016;2016:1-3. | 42.00 | YR | M | Y | 0.00000 | 20160915 | MD | PK | PK |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127477401 | 12747740 | 1 | PS | METFORMIN HYDROCHLORIDE. | METFORMIN HYDROCHLORIDE | 1 | Y | 78422 | 750 | MG | BID | ||||||||
| 127477401 | 12747740 | 2 | SS | METFORMIN HYDROCHLORIDE. | METFORMIN HYDROCHLORIDE | 1 | Y | 78422 | 1000 | MG | BID | ||||||||
| 127477401 | 12747740 | 3 | SS | EMPAGLI?OZIN | EMPAGLIFLOZIN | 1 | Y | 0 | 25 | MG | QD | ||||||||
| 127477401 | 12747740 | 4 | C | PIOGLITAZONE. | PIOGLITAZONE | 1 | Y | 0 | 30 | MG | QD | ||||||||
| 127477401 | 12747740 | 5 | C | Insulin glargine | INSULIN GLARGINE | 1 | Y | 0 | 40 | IU | INJECTION | ||||||||
| 127477401 | 12747740 | 6 | C | Insulin glargine | INSULIN GLARGINE | 1 | Y | 0 | 20 | IU | |||||||||
| 127477401 | 12747740 | 7 | C | Insulin aspart | INSULIN ASPART | 1 | 12 IU BEFORE BREAKFAST, 18 IU BEFORE LUNCH AND 24 IU BEFORE DINNER | Y | 0 | INJECTION | |||||||||
| 127477401 | 12747740 | 8 | C | Insulin aspart | INSULIN ASPART | 1 | Y | 0 | |||||||||||
| 127477401 | 12747740 | 9 | C | Liraglutide | LIRAGLUTIDE | 1 | 0 | .6 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127477401 | 12747740 | 1 | Type 2 diabetes mellitus |
| 127477401 | 12747740 | 3 | Type 2 diabetes mellitus |
| 127477401 | 12747740 | 5 | Type 2 diabetes mellitus |
| 127477401 | 12747740 | 7 | Type 2 diabetes mellitus |
| 127477401 | 12747740 | 9 | Weight decreased |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127477401 | 12747740 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127477401 | 12747740 | Diabetic ketoacidosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |